Projects per year
Abstract
Prostate cancer is a common malignancy, but only some tumors are lethal. Accurately identifying these tumors will improve clinical practice and instruct research. Aggressive cancers often have distinctive pathologies, including intraductal carcinoma of the prostate (IDC-P) and ductal adenocarcinoma. Here, we review the importance of these pathologies because they are often overlooked, especially in genomics and preclinical testing. Pathology, genomics, and patient-derived models show that IDC-P and ductal adenocarcinoma accompany multiple markers of poor prognosis. Consequently, "knowing what is growing" will help translate preclinical research to pinpoint and treat high-risk prostate cancer in the clinic.
Original language | English |
---|---|
Article number | aaz0152 |
Number of pages | 15 |
Journal | Science Translational Medicine |
Volume | 12 |
Issue number | 533 |
DOIs | |
Publication status | Published - 4 Mar 2020 |
Projects
- 1 Finished
-
Intraductal carcinoma of the prostate: indicator of aggressive disease.
Risbridger, G. (Primary Chief Investigator (PCI)), Bolton, D. M. (Chief Investigator (CI)), Bristow, R. (Chief Investigator (CI)), Clouston, D. (Chief Investigator (CI)), Frydenberg, M. (Chief Investigator (CI)), Murphy, D. G. (Chief Investigator (CI)) & Taylor, R. (Chief Investigator (CI))
National Health and Medical Research Council (NHMRC) (Australia)
1/01/15 → 31/12/18
Project: Research
Equipment
-
Monash Histology Platform (MHP)
Cohen, C. (Manager)
Faculty of Medicine Nursing and Health Sciences Research PlatformsFacility/equipment: Facility